deprexis®

Product Overview

Medical condition:

Depression as either a primary or secondary diagnosis.

Target patient population:

Individuals 18 years of age or older experiencing a depressive episode by itself or along with another medical condition.

What to expect:

Using cognitive behavioral therapy-based techniques, as well as AI to personalize the experience, deprexis® helps patients with depression learn how to overcome negative thoughts and behavior patterns.

Note: for more information, please visit https://orexo.com/digital-therapies/deprexis/.

Clinical Overview

Indications for use:

deprexis^® is intended as adjunctive treatment of chronic or recurrent depression or depressive disorders as a primary or secondary diagnosis (e.g. as a comorbidity in multiple sclerosis or epilepsy) for patients 18 years of age or older who are experiencing a depressive episode.

Outcomes:

deprexis^®, evaluated in more than 2800 individuals with depression across 11 clinical trials, has demonstrated efficacy to help reduce depression symptoms as an adjunct to treatment in varying populations and care settings.

Directions:

Once registered, users will have access to deprexis^® for 12 weeks. deprexis^® guides users through the program in a dynamic dialog and no special computer skills are required. An overview of the program is provided, after which the individual begins working and learning with deprexis^®, completing the modules as directed by the program.

The program will track progress and continue to guide the individual through the modules. Each module informs the user when the session is completed. All information entered is private to the user.

It is recommended for the user to use deprexis^® 1-2 times per week for at least half an hour per session.

Risks & warnings:

deprexis^® should not be used by patients with bipolar disorder, psychotic disorder (e.g. schizophrenia) or by patients with suicidal risk.

Progress with deprexis^® is based on many individual factors, and it is possible that not every individual will benefit from using the program. Not every exercise or recommendation is equally suitable for each user.

deprexis^® is not intended to replace current treatment, and is not a substitute for clinical care administered by an appropriate healthcare professional.

Place in therapy:

deprexis^® is intended as an adjunctive treatment.

Disclaimer: deprexis^® is not a healthcare provider and does not provide medical advice, diagnosis, or standalone treatment.

Product Access

Product description:

deprexis^® is an internet-based software platform that provides personalized CBT-based support to help improve depression symptoms. The 12-week program can be accessed on a desktop, laptop, smartphone, or tablet with internet access as well as an up-to-date browser. You also need an email address, and optionally a mobile number, for the text message service.

Prescription status:

A prescription is not required.

Patient access:

deprexis^® can be accessed via desktop, laptop, mobile phone, or tablet PC, using an up-to-date browser (Google Chrome, Mozilla Firefox, Internet Explorer, or Safari).

Individuals can obtain deprexis^® directly by visiting us.deprexis.com and selecting “Get deprexis”. Coverage support is provided to help determine if all or part of the cost can be covered by health insurance. No prescription is required.

Once acquired, users receive an email with an individualized access key and a link to the product website (deprexis.broca.io) to register and begin using the program.

Provider access:

Use of deprexis^® is completely confidential to the user. Healthcare providers will not have access to the information inputted into the program. It is at the discretion of the user whether they would like to share program materials or information contained within deprexis^®.

deprexis^® is to be used as part of the overall treatment plan for depression in conjunction with other treatment options.

Coverage options:

deprexis^® may be covered partially or fully by health insurance. Alternatively, individuals can pay for it directly.

Product availability:

deprexis^® is available in:  

• USA: under FDA enforcement discretion
• Germany and Switzerland: CE marked

Clinical Trials

The provided set of evidence represents a sample of conducted studies. For a comprehensive collection contact manufacturers directly.

• Study Title: Effectiveness of an internet intervention (Deprexis) for depression in a United States adult sample
  Study Design: Parallel-group, pragmatic randomized controlled trial
  Outcomes:In participants with moderate depression (Quick Inventory of Depression Symptomatology (QIDS) ≥ 10), use of deprexis^® for 8 weeks produced a statistically significant reduction in depressive symptoms when compared to the waitlist care-as-usual control group based on both self and clinician assessments (p<.001). The deprexis^® group had a 12x greater likelihood of experiencing at least 50% symptom improvement compared with the control group.
• Study Title: Effect of an internet intervention (Deprexis) on severe depression symptoms.
  Study Design:Parallel-group, pragmatic randomized controlled trial
  Outcomes:In participants with moderately severe and severe depressive symptoms, use of deprexis^® resulted in a significantly lower depression score at 12 weeks, compared to the care-as-usual control group (p<.01). Results were maintained up to the 6-month follow-up.
• Study Title: Effectiveness of a tailored, integrative internet intervention (deprexis) for depression 
  Study Design: Meta-analysis
  Outcomes: Meta-analysis of twelve deprexis^®-specific randomized controlled trials confirmed the effectiveness of deprexis^® for reduction of depressive symptoms over a period of 8 to 12 weeks across a broad range of initial symptom severity and can be effectively combined with varying forms of depression treatment.

Note: for more research, please visit: https://orexo.com/digital-therapies/deprexis/.